Clinical trials: Pharyngeal Cancer
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma
- Trial name
- NCT07667400
- Testing
- SX-682, DTX
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Oropharyngeal Squamous Cell Carcinoma, Human Papillomavirus Infection
Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer
The purpose of this research study is to determine if saliva and oral swab samples can be used to detect human papillomavirus in patients with cancer.
- Trial name
- NCT06362421
- Testing
- Pre-Radiation Dental Evaluation/Sample Collection, Pre-Study Visit, Oral Medicine Consultation Visit/Sample Collection
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Cancer, Oral Cavity Cancer
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate if the addition of valproic acid to standard platinum-based chemoradiation as definitive treatment of locally advanced Head and Neck squamous cell carcinoma can improve treatment outcomes…
- Conditions
- Head and Neck Cancer, Oral Cavity Cancer, Oropharyngeal Cancer
- Trial name
- NCT01695122
- Testing
- Valproic Acid
- Where
- Brazil
- Volunteers
- 14 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Oropharynx Cancer
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
The majority of head and neck cancer patients do not respond to immunotherapies, and clinical responses are often not durable. However, targeting tumors with stereotactic radiation in combination with immunotherapy while sparing…
- Trial name
- NCT05787639
- Testing
- Evorpacept
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Diego
Cranial Nerve Injury, Oropharyngeal Cancer
Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)
The goal of this clinical research study is to learn about possible intervention strategies to help control cranial neuropathy in patients after they receive radiation therapy for OPC.
- Trial name
- NCT07832266
- Testing
- Prednisone, Ajovy, Manual Therapy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Nasopharyngeal Carcinoma by AJCC V8 Stage
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT05717790
- Testing
- Nimotuzumab, Gemcitabine, Cisplatin
- Where
- 9 sites in China
- Volunteers
- 288 people
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
Oropharynx Cancer
Proteome- and Methylation Profiles in Oropharyngeal Cancer
This clinical study aims to evaluate proteome- and methylation profiles in saliva in patients with oropharyngeal cancers
- Trial name
- PROMEO (NCT04567082)
- Testing
- Examination of saliva
- Where
- Denmark
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Aalborg University Hospital
Head and Neck Cancer
Nutritional Status and Barriers to Dietary Intake in Head and Neck Cancer Patients
The investigators hope to learn more about how side-effects of RT or RTchemo affect food intake and nutrition status.
- Trial name
- NCT00375180
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- AHS Cancer Control Alberta
Nasopharyngeal Carcinoma
SOX as Salvage Treatment in Nasopharyngeal Carcinoma
The aim of the study is to evaluate the efficacy and safety of SOX regimen (S-1 plus oxaliplatin) as salvage treatment in patients with relapsed or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT01403259
- Testing
- S-1 plus oxaliplatin
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma, Malnutrition
The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients
The purpose of this study is to study the function of pre-albumin, retinol conjugated protein and transferrin in early malnutrition detecting and nutritional status dynamic monitoring for local advanced nasopharyngeal carcinoma…
- Trial name
- NCT03240835
- Testing
- cisplatin and docetaxel, IMRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhao Chong
Hypopharyngeal Carcinoma
Neck Dissection vs Radiotherapy for Cervical Metastases in Advanced Hypopharyngeal Cancer
At the time of diagnosis, approximately 60%-80% of patients with hypopharyngeal cancer are found with cervical lymph node metastasis. Cervical nodal metastasis is an important prognostic factor in hypopharyngeal cancer.
- Trial name
- NCT03367884
- Testing
- Neck dissection followed by radiotherapy(50Gy) according to risk factors, Definitive radiotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Head and Neck Cancer, Oral Complications
Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
RATIONALE: Sargramostim may lessen symptoms of mucositis in patients receiving radiation therapy for head and neck cancer. It is not yet known if sargramostim is more effective than no treatment in reducing mucositis caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00008398
- Testing
- sargramostim, quality-of-life assessment, radiation therapy
- Where
- 236 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Upper Aerodigestive Tract Lesions, Neoplasms, Oropharyngeal
Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract
This study will compare TNFE-NBI and biopsy, with DRE and biopsy for the diagnostic evaluation and staging of patients with suspicious UADT lesions.
- Conditions
- Upper Aerodigestive Tract Lesions, Neoplasms, Oropharyngeal, Oropharyngeal Cancer, Neoplasms, Hypopharyngeal
- Trial name
- TNFE-NBI (NCT01175499)
- Testing
- Direct Rigid Endoscopy, Transnasal Flexible Endoscopy with Narrowband Imaging
- Sponsor
- University of California, San Francisco
Oropharyngeal Cancer, Human Papillomavirus
Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time
This research is being done to understand more about a sexually transmitted virus called Human papillomavirus (HPV) in people with oropharyngeal cancer and their partners.
- Trial name
- HOTSPOT (NCT01342978)
- Where
- 4 sites in United States
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
VK-2019-001 is a 1/2a trial of the oral EBNA-1 targeting agent VK-2019 in patients with EBV-positive recurrent or metastatic NPC to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D), as well as to…
- Trial name
- NCT03682055
- Testing
- VK-2019
- Where
- 6 sites in United States, China and 3 more
- Volunteers
- 14 people
- Sponsor
- Cullinan Therapeutics Inc.
Nasopharyngeal Carcinoma
Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy
Currently, concurrent chemoradiotherapy with/without sequential chemotherapy is the standard treatment modality for intermediate risk NPC (stage II and T3N0M0) according to the National Comprehensive Cancer Network guideline.
- Trial name
- NCT02289807
- Testing
- Cisplatin, IMRT
- Where
- China
- Sponsor
- Sun Yat-sen University
Malignant Neoplasm of Nasopharynx
A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients
The chemo-radiotherapy for the local advanced nasopharyngeal carcinoma patients will induce the mucosal ulcer and damage salivary glands. Consequently, it can disturb the nutrition conditions and clinical outcomes of patients.
- Trial name
- NCT02948699
- Testing
- Nutrison
- Where
- 2 sites in China
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Zhejiang Cancer Hospital
Hypothyroidism, Complications
Post-radiation Hypothyroidism After IMRT for Nasopharyngeal Carcinoma
The investigators evaluate if there are radiation dosimetric parameters for the prediction of biochemical and clinical hypothyroidism after intensity-modulated radiation therapy (IMRT) for non-metastatic nasopharyngeal carcinoma…
- Trial name
- NCT02689609
- Testing
- Intensity-modulated radiation therapy
- Volunteers
- 149 people
- Sponsor
- The University of Hong Kong
Nasopharyngeal Carcinoma (NPC)
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
The aim of this study is to evaluate the efficacy, adverse reactions, nutritional status analysis, and quality of life analysis of Toripalimab Plus Induction Chemotherapy Followed by Radiation Therapy Combined with Omega-3 in the…
- Trial name
- NCT07136519
- Testing
- Toripalimab, Omega-3, radiotherapy
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Nasopharyngeal Carcinoma
Umbrella Biomarker-Guided Therapy in NPC
This is a phase 2, open-label, umbrella study, with the purpose to evaluate the therapeutic efficacy and safety of chemoradiotherapy in combination with immunotherapy and/or targeted treatment in high-risk locoregionally advanced…
- Trial name
- NCT04605562
- Testing
- GP+DDP, Palbociclib, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.